The umbilical cord blood is now a renowned source of stem cells that can be used for hematopoietic stem cell transplantation. Because of cord blood advantages, including immediate availability and higher degree of acceptable HLA mismatch, the number of patients who received such treatment is constantly growing. The limitations of cord blood usage still exist, however laboratory and clinical trials all over the world try to overcome that barriers. Owing to international cooperation of stem cell banks, umbilical cord-derived stem cells from FamiCord Group were used in clinical trials of hematopoietic stem cell transplantations. Ten transplantations, including one autologous, took place in Poland, while the other three were carried out in Hungary. The most common indication was acute leukemia, however among children with hematologic diseases there were also patients with histiocytosis, chronic granulomatous disease or hypoxic ischaemic encephalopathy. Currently many scientists explore the possibilities of umbilical cord stem cell potential clinical usage with promising results.
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The hematopoietic stem cell transplantation with umbilical cord blood (UCB-HSCT) as a source is a rapidly developing method that enables finding a donor for larger group of patients. Up to date, over 25000 hematopoietic stem cell transplantations (HSCT) with umbilical cord blood (UCB) as a source of cells have been performed. The UCB is nowadays in the scientific spotlight because of its advantages: no adverse effects on the stem cell donor, immediate availability, greater degree of HLA disparity, low risk of pathogen transmission and relatively low risk of developing graft-versus-host disease (GvHD).
On the other hand, limitations of UCB usage still exist. The limited number of cells results in poorer homing and engraftment that puts patients at susceptibility of developing life-threatening infections due to prolonged neutropenia [1, 2] . However, many new procedures are now in the phase of a clinical trial with the objective to overcome those limitations [3] . That can be achieved by increasing the number of infused CD34 + cells (double umbilical cord blood transplantation), enhancing homing (dipeptidylpeptidase IV inhibitors, complement C3a), ex vivo expansion of stem cells with growth factors and cytokines, influencing bone marrow microenvironment (intra-bone infusion, co-transplantation with mesenchymal stem cells), promoting undifferentiated state of progenitor cells (Notch ligand, nicotinamide, copper chelators, aryl hydrocarbon receptor antagonists) or other methods such as manipulations with α-1,3-fucosyltransferase VI and prostaglandin E2 [4] [5] [6] [7] [8] [9] [10] [11] [12] .
The UCB collection is an easy and safe procedure with no risk to the donor. The blood is collected to the special kit by the umbilical cord puncture from the navel-string vessel after the omphalotomy. The collected cells are processed and cryopreserved in a liquid nitrogen and they can by applied even after 23,5 years [13] . The preliminary evaluation of umbilical cord blood as a biological material for transplantation is based on the obtained volume and number of leukocytes in a microliter. However, an unequivocal assessment can be done after determining the exact number of CD34 + cells. The first attempt of umbilical cord blood transplantation was undertaken in 1970, in a boy treated due to leukemia. Eight units of cord blood had been transplanted in intervals of about dozen days with preceding chemotherapy based only on encorton and 6-mercaptopurine, without any kind of preparative regimen [14] . The first successful transplantation was conducted by E. Gluckman at the initiative of H. Broxmeyer and J. Kurtzberg. The patient was a 5-year-old boy with Fanconi anemia, he received his new-born sisters' cord blood [15] . Nowadays the patient still remains in a good health condition. The first unrelated allogeneic stem cell transplantation was carried out five years later in two patients with high risk leukemia [16] . However, the first autologous HSCT was conducted in Brasil: the recipient was a girl with neuroblastoma, whose cord blood was preserved with the objective of treating her older brother suffering from leukemia [17] .
Indications for UCB-HSCT are the same as those for bone marrow or peripheral blood stem cell transplantation. European Bone Marrow and Blood Transplantation Group (EBMT) published its first two reports without distinguishing the type of source for HSCT [18, 19] . For the first time, in 2002, EBMT report officially distinguished three stem cell (SC) sources and described conditions which have to be fulfilled when cord blood is chosen as a cell source for HSCT [20] . Cord blood as an alternative stem cell source is used for treating a variety of malignant or non-malignant diseases as well as hematologic disorders. The penultimate EMBT report in 2006 confirmed that the recommendations for UCB-HSCT are the same as for bone marrow or peripheral blood hematopoietic stem cell transplantation [21] . According to Gratwohl study, main causes of UCB-HSCT in Europe were due to non-malignant disorders (leading in the group of related transplantations), acute leukemia (leading in the group of unrelated transplantations) and lymphoproliferative diseases [22] .
Nowadays, the number of patients after UCB transplantations continues to increase. According to Eurocord data, 8007 patients have been treated with UCB-HSCT until the end of 2011 year, using 10651 cord blood units. The number of transplantations worldwide exceeded 25000 procedures until the end of 2012 [23] .
The FamiCord Group donated cord blood units for 13 umbilical cord hematopoietic stem cell transplantations. We would like to share our experience concerning clinical use of umbilical cord blood-derived stem cells. . No adverse effects were noticed after transplantation, patient did not develop GvHD. The recipient was discharged in a good general condition +48 days after transplantation [25] .
The first transplantation of
The third transplantation was the first autologous one. It was performed in a 16-month-old child with hypoxic-ischemic encephalopathy after cardiac arrest 7 months before. The recent experimental results showed that human umbilical cord blood derivatives transplantation can be proposed as a new treatment for a stroke. The procedure was approved by Review Board of Ethics Committee and carried out by Children's Memorial Health Institute in Warsaw. The patient was in a permanent vegetative state with a severe epileptic seizures and an unsatisfying drug control. The cells from the autologous umbilical cord blood were neurologically restricted by a 10-day culture in neurogenic conditions. To enable engraftment tracking with MRI, the cells were labeled with iron oxide nanoparticles. The patient received three serial injections into lateral ventricle of the brain containing 1,2•10 6 cells/0,5 ml with 1 month intervals. There were no adverse effects apart from transient fever not exceeding 38 o C. The MRI examination showed hypointense areas appearing immediately after injection that persisted up to 4 months after the procedure. The neurological state of the child has slightly improved during 6 month follow-up: he responded to the mother voice through smiling, the seizures were reduced by 50 %, the nystagmus was less pronounced and the spasticity was milder. Although the child still was severally impaired, it no longer fulfilled the diagnostic criteria of a vegetative state. There is a strong need of further studies that will determine benefits coming from this approach [26] .
The 6 CD34 + cells/kg body weight. Neutrophil recovery was achieved on +18 th day and primary results showed complete chimerism of donor origin. The peritransplant period was complicated by BKV-associated hemorrhagic cystitis and asymptomatic CMV reactivation. However, a mixed chimerism with an increasing number of autologous cells was observed and therefore, on the +139 th day posttransplant, the patient received donor lymphocyte infusion with the cell dose of 1•10 6 CD3 cells/ kg body weight.
The seventh transplantation was the second one from a public bank in Hungary. It was carried out on April the 14 th , 2011. The patient was a girl with trisomy 21, treated due to thrombocytopenia since birth and diagnosed with MDS that transformed into minimally differentiated acute myeloid leukaemia after 3 months. The patient was treated according to AML-BFM-98 protocol and archived remission, however minimal residual disease persisted. The girl was qualified for HSCT and her brother turned out to be HLA-identical donor, therefore his stored cord blood have been planned as a SC source. The busulphan-fludarabinecyclophosphamide-based conditioning was applied. The HSCT was performed with CD34 + cell dose of 6,8•10 5 /kg body weight. No early adverse effects were observed. With lower grade of expected GvHD after UCB-HSCT, the child received only cyclosporine, without metothrexate as a GvHD prophylaxis. High fever was observed on the +7 th day after transplantation, and the antibiotic therapy was changed from the empiric to the aimed one. The girl received also antihypertensive treatment due to headaches connected with high blood pressure. Neutrophil engraftment was observed on +14 th day, however the patient received parenteral filgrastim in the meantime. The patient developed skin lesions of stage I GvHD and thus received methyl-prednisone with gradually decreasing doses and topical tacrolimus. The treatment was discontinued at +44 5 CD34 + with cell viability of 99%. At the time of writing, over nearly 2 years after transplantation, the patient is alive and remains in complete remission of disease.
The tenth patient was a 7-year-old boy with chronic granulomatous disease (CGD), who presented with pneumonia, otitis, laryngitis and chronic lymphadenopathy at the age of 2. Multiple granulomas in lungs and intestines had been detected and the diagnose of CGD was established. The FamiCord Group transplantations were the first procedures with a SC source coming from a private bank both in Poland and Hungary. Moreover, it was a first and second time in Poland to use cord blood combined with bone marrow from the same donor (in children). This kind of procedure is considered safe and effective, moreover, the bone marrow harvesting is much less traumatic for a donor, because only a supplementary number of CD34 + has to be collected [29] . Among FamiCord Group transplantations there were two with contaminated at the day of delivery cord blood (in Poland with Propionibacterium acnes and in Hungary with Streptococcus agalactiae). No serious adverse effects and no evidence of bacteria in recipient's peripheral blood were observed.
There are many studies concerning HSCT with contaminated stem cell products, however the final decision about transplantation lies in the hands of a transplant center and is made individually for each patient. The choice about banking an infected cord blood portion is made by parents after a consultation with a doctor, who provides them with information about the type of microbe and its antibiogram in a case of bacterial contamination. The reported results of HSCT with contaminated stem cell product remains good for a majority of procedures [30] . Klein et al. study analyzed the clinical outcomes of hematopoietic stem cell transplantations of contaminated products in years 1990-2004. A total number of 35 patients received infected material with coagulase-negatvie Staphyloccocus as a predominant species isolated, the transplantation was preceded by prophylactic antibiotic therapy. All patients had benign post-transplant courses apart from one patient with Pseudomonas bacteriemia who died because of complications [31] [36] .
